Anderson Sarah L, Trujillo Jennifer M
University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Mail Stop C238, 12850 East Montview Blvd., Aurora, CO, USA.
Ther Adv Chronic Dis. 2016 Jan;7(1):4-17. doi: 10.1177/2040622315609312.
Type 2 diabetes (T2D) is a highly prevalent disorder that affects millions of people worldwide. The hallmark of T2D is hyperglycemia and, while many treatment modalities exist, achieving and maintaining glycemic control can be challenging. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an appealing treatment option as they improve glycemic control, reduce weight, and limit the risk of hypoglycemia. Lixisenatide is a once-daily GLP-1 RA that has been evaluated in the GetGoal clinical trial program and has demonstrated efficacy and tolerability across a spectrum of patients. The feature that most distinguishes lixisenatide from other GLP-1 RAs is its ability to substantially reduce postprandial glucose (PPG) for the meal immediately following injection. Because of its positive effects on PPG, lixisenatide is being considered as a replacement for prandial insulin, and a fixed dose combination product containing lixisenatide and basal insulin is in development. Lixisenatide is a promising new addition to the antidiabetic armamentarium, but due to the lack of real-world experience with the drug, its exact place in therapy is unknown.
2型糖尿病（T2D）是一种非常普遍的疾病，影响着全球数百万人。T2D的标志是高血糖，虽然存在多种治疗方式，但实现并维持血糖控制可能具有挑战性。胰高血糖素样肽-1（GLP-1）受体激动剂（RAs）是一种有吸引力的治疗选择，因为它们可改善血糖控制、减轻体重并降低低血糖风险。利司那肽是一种每日一次的GLP-1 RA，已在GetGoal临床试验项目中进行了评估，并在各类患者中显示出疗效和耐受性。利司那肽与其他GLP-1 RAs最显著的区别在于，它能够在注射后的下一餐中大幅降低餐后血糖（PPG）。由于其对PPG有积极作用，利司那肽正被考虑作为餐时胰岛素的替代品，并且一种含有利司那肽和基础胰岛素的固定剂量复方产品正在研发中。利司那肽是抗糖尿病药物库中一个有前景的新成员，但由于缺乏该药物的真实世界经验，其在治疗中的确切地位尚不清楚。
